Mutations in the TP53 tumor supressor gene usually occur within the highly conserved DNA-binding domain (aa 100–298) and, when inherited, are typically associated with Li-Fraumeni syndrome (LFS), in which carriers develop a broad spectrum of cancers (e.g., breast, brain, soft tissue, bone, blood, and adrenal cortex tumors) during childhood or young adulthood [1]. This evidence concerns the gene TP53 and Li-Fraumeni syndrome.